Latest Watson Pharmaceuticals Stories
NEW YORK, March 15, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Questcor Pharmaceuticals Inc. (NASDAQ:QCOR), Actavis Inc. (NYSE:ACT), American International Group Inc. (NYSE:AIG), ACE Limited (NYSE:ACE) and Flowers Foods, Inc. (NYSE:FLO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Questcor Pharmaceuticals Inc. Research...
PARSIPPANY, N.J., Feb. 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone(®). Actavis intends to begin shipping the product immediately. Suboxone(®) is indicated for maintenance treatment...
PARSIPPANY, N.J, Feb. 14, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo(®) (Hydromorphone Hydrochloride Extended-Release) tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Mallinckrodt...
BOCA RATON, Fla., Feb. 13, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Pioglitazone Hydrochloride Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Synthon Pharmaceuticals, Inc., and will be available in 15 mg, 30 mg, and 45 mg strengths. Breckenridge is launching its ANDA prior to patent expiration pursuant to a...
PARSIPPANY, N.J., Jan. 31, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found United States Patent No. 5,100,899 (the '899 Patent) valid and infringed by Actavis' generic version of Pfizer Inc.'s Rapamune® (sirolimus). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal. Rapamune® tablets are indicated for the prophylaxis...
PARSIPPANY, N.J., Jan. 24, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. today announced that the company has adopted Actavis, Inc. (NYSE: ACT) as its new global name and will today begin trading under a new symbol -- ACT -- on the New York Stock Exchange. The company first announced its intention to change its name last year, following its acquisition of the Actavis Group. The combination created the world's third largest generic pharmaceutical company, with anticipated...
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets. Actavis' ANDA product is a generic version of the currently marketed formulation of Endo Health Solutions' Opana(®) ER,...
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential future milestone payments. The acquisition of Uteron expands Watson's Global Brands pipeline of Women's Health products including two potential near term global commercial opportunities in contraception and infertility, and one novel...
LONDON, January 18, 2013 /PRNewswire/ -- The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers in the past years and this trend is expected to go for some years to come. In 2012 alone, over 40 branded drugs with a $35 billion yearly sales tag have lost patent protection. StockCall has technical coverage on two of the biggest generic makers, Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is...
PARSIPPANY, N.J., Jan. 11, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 25, 2013 in New York. The meeting will begin at 8:00 a.m. EST and will be webcast simultaneously. The meeting will be hosted by Watson's executive leadership team and will offer an in-depth look into the combined company following the acquisition of the Actavis Group. Paul...
